ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Mar 15, 2022 13:03 JST
Source: Eisai
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
TOKYO, Mar 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown in the table below.
Economic arrangements for 2022 will remain materially unchanged with Eisai's share of ADUHELM expenses capped at $335 million for the costs related to development, commercialization and manufacturing for the period from January 1, 2022, to December 31, 2022.
In regards to Eisai's financials, no revision will be made at this time to the consolidated earnings forecast for the fiscal year ending March 31, 2022. If Eisai determines that revisions are necessary based on changes including business environment, Eisai will make an announcement as soon as possible.
*ADUHELM is a registered trademark of Biogen Inc.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Sectors: BioTech
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MC and Maruha Nichiro Agree to Establish New Joint Venture in Salmon (land-based)
Jun 30, 2022 18:23 JST
DOCOMO and CyberAgent to Establish New Advertising Company: Prism Partner Inc.
Jun 30, 2022 18:04 JST
MHIENG's First Compact CO2 Capture System Goes into Commercial Operation at Biomass Power Plant in Hiroshima
Jun 30, 2022 14:44 JST
Mazda Production and Sales Results for May 2022
Jun 30, 2022 13:33 JST
Milestone of THz Communication
Jun 29, 2022 16:48 JST
Infinera and NEC to Modernize Neutral Networks' Mexico to United States Fiber Optic Network with Industry-leading ICE6 800G Solution
Jun 29, 2022 15:35 JST
Fujitsu Recognized as Winner of 2022 Microsoft Education Partner of the Year Award
Jun 29, 2022 11:18 JST
Hitachi High-Tech Launches the AFM100 Pro High-Sensitivity Scanning Probe Microscope System with Improved Detection Sensitivity
Jun 28, 2022 16:51 JST
Hokkaido University and NEC conclude an agreement for developing spatial sensing to combat the spread of illness
Jun 28, 2022 15:53 JST
Fujitsu global survey demonstrates how 'digital first' approach helps to accelerate sustainability transformation
Jun 28, 2022 12:26 JST
E.Design Insurance and Eisai Enter Into Business Alliance
Jun 28, 2022 10:20 JST
GR YARIS Rally1 wins African epic with incredible 1-2-3-4 finish
Jun 27, 2022 10:50 JST
Toyota and Suzuki to Deepen Collaboration in the Fields of Development and Production in India
Jun 24, 2022 19:16 JST
Murata and Mitsubishi Agree on a Cooperative Framework for Working Toward a Carbon-Neutral Society
Jun 24, 2022 18:22 JST
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Jun 24, 2022 11:55 JST
Honda Joins Sustainable Aviation Fuel Review Panel
Jun 24, 2022 10:42 JST
TOYOTA GAZOO Racing announces team setup for Nurburgring Endurance Series
Jun 23, 2022 17:54 JST
MHI Invests in Electric Hydrogen, a U.S. Startup, to Accelerate Efforts to Produce Clean Hydrogen at Scale
Jun 23, 2022 14:31 JST
MHI Thermal Systems' Plug-in Hybrid Transport Refrigeration Units Receive Technology Award from Japan Society of Refrigerating and Air Conditioning Engineers
Jun 23, 2022 12:37 JST
MHI and Chugoku Electric Conclude Basic Agreement toward 100% Renewable Energy Usage at Mihara Machinery Works
Jun 23, 2022 11:34 JST
More Latest Release >>
Related Release
E.Design Insurance and Eisai Enter Into Business Alliance
6/28/2022 10:20:00 AM JST
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
6/24/2022 11:55:00 AM JST
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
6/22/2022 2:05:00 PM JST
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
6/6/2022 3:05:00 PM JST
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
6/3/2022 4:37:00 PM JST
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
5/27/2022 12:49:00 PM JST
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
5/27/2022 12:24:00 PM JST
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
5/10/2022 11:23:00 AM JST
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
5/10/2022 11:00:00 AM JST
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
4/1/2022 2:05:00 PM JST
More Press release >>